RayzeBio Common Stock Analysis
RayzeBio Common's financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. RayzeBio Common's financial risk is the risk to RayzeBio Common stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Given that RayzeBio Common's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which RayzeBio Common is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of RayzeBio Common to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, RayzeBio Common is said to be less leveraged. If creditors hold a majority of RayzeBio Common's assets, the Company is said to be highly leveraged.
RayzeBio Common Stock is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of RayzeBio Common delisted stock analysis is to determine its intrinsic value, which is an estimate of what RayzeBio Common Stock is worth, separate from its market price. There are two main types of RayzeBio Common's stock analysis: fundamental analysis and technical analysis.
The RayzeBio Common stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and RayzeBio Common's ongoing operational relationships across important fundamental and technical indicators.
RayzeBio |
RayzeBio Stock Analysis Notes
About 90.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.08. RayzeBio Common Stock had not issued any dividends in recent years. To find out more about RayzeBio Common Stock contact Kenneth MD at 619-937-2754 or learn more at https://rayzebio.com.RayzeBio Common Stock Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. RayzeBio Common's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding RayzeBio Common Stock or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| RayzeBio Common is not yet fully synchronised with the market data | |
| RayzeBio Common has some characteristics of a very speculative penny stock | |
| RayzeBio Common has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (63.5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| RayzeBio Common generates negative cash flow from operations | |
| Over 90.0% of the company shares are owned by institutional investors |
RayzeBio Common Stock Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to RayzeBio Common previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
RayzeBio Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.72 B.RayzeBio Common Stock Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific RayzeBio Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on RayzeBio Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases RayzeBio Common insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arvind Kush over a year ago Disposition of 78433 shares by Arvind Kush of RayzeBio Common subject to Rule 16b-3 | ||
Moran Susan over a year ago Exercise or conversion by Moran Susan of 30875 shares of RayzeBio Common subject to Rule 16b-3 | ||
Viking Global Investors Lp over a year ago Conversion by Viking Global Investors Lp of 1285223 shares of RayzeBio Common | ||
Katabi Maha over a year ago Acquisition by Katabi Maha of 18235 shares of RayzeBio Common subject to Rule 16b-3 | ||
Van Hauwermeiren Timothy over a year ago Acquisition by Van Hauwermeiren Timothy of 48628 shares of RayzeBio Common subject to Rule 16b-3 | ||
Katabi Maha over a year ago Conversion by Katabi Maha of 973653 shares of RayzeBio Common | ||
Wellington Biomedical Innovation Master Investors Cayman Ii Lp over a year ago Conversion by Wellington Biomedical Innovation Master Investors Cayman Ii Lp of 1557846 shares of RayzeBio, Common | ||
Heyman Richard A over a year ago RayzeBio, Common exotic insider transaction detected |
RayzeBio Common Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the RayzeBio Common's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of RayzeBio Common, which in turn will lower the firm's financial flexibility.Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding RayzeBio Common to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Options Analysis Now
Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios |
| All Next | Launch Module |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in RayzeBio Stock
If you are still planning to invest in RayzeBio Common Stock check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RayzeBio Common's history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |